- Happy Holidays from all of us at the IMF. We wish you comfort and joy wherever and however you may celebrate. And we promise that we will be working hard in 2006 to make your New Year bright; because until there is a cure...there is the IMF.
- IMF to Establish European Base of Operations in Germany
The IMF has been increasingly active in Europe. Within the last five years, Patient and Family Seminars, Scientific Myeloma Symposia, and Myeloma Conferences have been held in Paris, Madrid, Barcelona, Zurich, Istanbul, St. Petersburg, Rome, Vienna, Heidelberg and Turin. In 2006, IMF activities are already slated for cities in Austria, France, Germany, Spain, Italy and the Czech Republic. A native of Germany, Gregor Brozeit, who currently is the Director of Public Advocacy for the IMF, will direct the European operations.
- IMF DNA Bank Identifies Genetic Variations Related to Predisposition to Myeloma and Response to Treatment
The findings,presented at the 47th Annual Meeting of the American Society of Hematology (ASH), identify individual genetic differences that may be associated with risk factors for developing myeloma and with adverse reactions to therapies in patients who have myeloma.
WHAT'S NEW IN RESEARCH
- Amgen Updates Product Prescribing Information for Aranesp (darbepoetin alfa)
Sections of the product prescribing information for Aranesp (darbepoetin alfa) have been updated regarding the fact that, recently, pure red cell aplasia (PRCA) and severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp.
- Lenalidomide and thalidomide: mechanisms of action-similarities and differences.
IMF Scientific Advisor, Anderson, KC
Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8.
- Bortezomib (Velcade) Shows Strong Survival Benefit in Relapsed Multiple Myeloma: Presented at ASH
Extended survival data from the international, Assessment of Proteasome Inhibition for Extending Remissions (APEX) indicate that the clinical benefits of bortezomib monotherapy in patients with relapsed multiple myeloma remain strong after extended follow-up.
- Treatment paradigms for the newly diagnosed patient with multiple myeloma
Semin Hematol. 2005 Oct;42(4 Suppl 4):S16-21.
- Flow cytometric detection of circulating myeloma cells pretransplant in patients with multiple myeloma: a simple risk stratification system
David Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, IMF Scientific Advisor S V Rajkumar, Philip R Greipp, Mark R Litzow, Dennis A Gastineau, Thomas E Witzig, and IMF Scientific Advisor Morie A Gertz
Blood published 8 December 2005, 10.1182/blood-2005-08-3398
- Apoptosis and complement mediated lysis of myeloma cells by polyclonal rabbit anti-thymocyte globulin
Martin S Zand, Thuong Vo, Tina Pellegrin, Raymond Felgar, Jane L Liesveld, J J Ifthikharuddin, Camille N Abboud, Ignacio Sanz, and Jennifer Huggins
Blood published 20 December 2005, 10.1182/blood-2005-06-2269
- New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals.
IMF Scientific Advisor Durie BG.
Clin Lymphoma Myeloma. 2005 Nov;6(3):181-90.
If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Tax-deductible donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.